Search results for "opioids"

showing 10 items of 40 documents

The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids

2017

Objective: The aim of this study was to prospectively assess the efficacy and safety of low doses of sublingual fentanyl (SLF) for the treatment of breakthrough pain (BTP) in cancer patients in patients who were receiving low opioid doses for background analgesia. Methods: A sample of cancer patients presenting BTP episodes and receiving stable low doses of opioids for background pain (less than 60 mg of oral morphine equivalents) was selected to assess the efficacy and safety of low doses of SLF (67 μg). For each patient, data from four consecutive episodes were collected. For each episode, changes in pain intensity and adverse effects when pain got severe (T0), and 5, 10, and 15 min a…

MaleBreakthrough-episodic pain; Cancer pain; Opioids; Sublingual tablet; OncologyBreakthrough PainPain medicineAdministration SublingualOpioidFentanyl03 medical and health sciences0302 clinical medicineBreakthrough-episodic painmedicineHumansIn patientProspective StudiesCancer painProspective cohort studySublingual tabletAgedbusiness.industryLow doseBreakthrough PainOpioidsAnalgesics OpioidFentanylProspective StudieOpioidOncology030220 oncology & carcinogenesisAnesthesiaFemaleCancer painbusiness030217 neurology & neurosurgerymedicine.drugHuman
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

The palliative-supportive care unit in a comprehensive cancer center as crossroad for patients' oncological pathway

2016

Aim The aim of this study was to assess how an admission to an acute palliative-supportive care unit (APSCU), may influence the therapeutic trajectory of advanced cancer patients. Methods A consecutive sample of advanced cancer patients admitted to APCU was assessed. The following parameters were collected: patients demographics, including age, gender, primary diagnosis, marital status, and educational level, performance status and reasons for and kind of admission, data about care-givers, recent anticancer treatments, being on/off treatment or uncertain, the previous care setting, who proposed the admission to APSCU. Physical and psychological symptoms were evaluated at admission and at ti…

MaleGenetics and Molecular Biology (all)Palliative careCancer Treatmentlcsh:MedicineMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)ToxicologyPathology and Laboratory MedicineBiochemistryCONSECUTIVE SAMPLE0302 clinical medicineNeoplasmsMedicine and Health SciencesMedicine030212 general & internal medicinelcsh:ScienceAnalgesicsMultidisciplinaryPharmaceuticsMedicine (all)Palliative CareHormonal TherapyDrugsHospitalsPatient DischargeHospitalizationOncologyCritical Pathway030220 oncology & carcinogenesisCritical PathwaysMarital statusHormonal therapyFemaleOff TreatmentEnd-of-life careResearch ArticleHumanmedicine.medical_specialtyPatientsAged; Analgesics; Female; Follow-Up Studies; Hospitalization; Humans; Male; Neoplasms; Patient Discharge; Patient Readmission; Cancer Care Facilities; Critical Pathways; Palliative Care; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Cancer Care FacilitiesPatient ReadmissionFollow-Up Studie03 medical and health sciencesDrug TherapyPain ManagementHumansIntensive care medicineAgedPharmacologyBiochemistry Genetics and Molecular Biology (all)ToxicityPerformance statusCancer Care Facilitiebusiness.industrylcsh:RBiology and Life SciencesCancermedicine.diseaseHealth CareOpioidsAgricultural and Biological Sciences (all)Health Care FacilitiesEmergency medicineNeoplasmlcsh:QAnalgesicbusinessFollow-Up Studies
researchProduct

The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

2013

Abstract The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from fou…

MalePain medicineSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataHome careFentanylDose-Response RelationshipBuccalBreakthrough-episodic painNeoplasmsmedicine80 and overHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalgesicsDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalBuccal administrationMiddle AgedFentanyl buccal tabletHome Care ServicesAnalgesics OpioidOpioidsFentanylRegimenTreatment OutcomeBasal (medicine)OpioidOncologyCancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home careAnesthesiaAdministrationFemaleBreakthrough-episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids; Administration Buccal; Aged; Aged 80 and over; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Home Care Services; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Treatment Outcome; OncologyDrugCancer painbusinessmedicine.drugTablets
researchProduct

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

2010

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging prob…

MalePalliative careBreakthrough PainAdministration OralPainDrug Administration ScheduleSex FactorsClinical ProtocolsMedicinebreakthrough pain; acute palliative care unit; opioidsHumansAgedPain MeasurementAnalgesicsDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsopioidsMiddle Agedacute palliative care unitbreakthrough painClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineNociceptionTreatment OutcomeBasal (medicine)OpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients. An Observational Study

2016

Abstract Context Episodic breathlessness is a relevant aspect in patients with advanced cancer. Objectives The aim of this study was to assess the different aspects of this clinical phenomenon. Methods A consecutive sample of patients with advanced cancer admitted to different settings for a period of six months was surveyed. The presence of background breathlessness and episodic breathlessness, their intensity (numerical scale 0–10), and drugs used for treatment were collected. Factors inducing episodic breathlessness and its influence on daily activities were investigated. Results Of 921 patients, 29.3% ( n  = 269) had breathlessness and 134 patients (49.8%) were receiving drugs for backg…

MalePediatricsmedicine.medical_specialtyPalliative careActivities of daily livingTime FactorsEpisodic breathlessneSettore MED/41 - AnestesiologiaContext (language use)advanced cancer; dyspnea; Episodic breathlessness; opioids; palliative care; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)DiseaseComorbidityepisodic breathlessness; advanced cancer; dyspnea; opioids; palliative care03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineNeoplasmsEpidemiologyActivities of Daily LivingmedicinePrevalenceHumansadvanced cancer030212 general & internal medicineKarnofsky Performance StatusGeneral NursingNursing (all)2901 Nursing (miscellaneous)Agedpalliative careEpisodic breathlessnessbusiness.industryEpisodic breathlessness; advanced cancer; dyspnea; opioids; palliative careopioidsCardiovascular Agentsrespiratory systemMiddle Ageddyspneamedicine.diseaseComorbidityAnesthesiology and Pain Medicine030220 oncology & carcinogenesisCardiovascular agentMultivariate AnalysisopioidObservational studyFemaleNeurology (clinical)business
researchProduct

Tapentadol in cancer pain management: a prospective open-label study.

2012

OBJECTIVES: The aim of this prospective, open-label study was to evaluate the efficacy and tolerability of tapentadol (TP) in the management of cancer pain. METHODS: A 4 weeks' prospective study was carried out in 50 opioid-naive cancer patients with moderate-severe pain. Each patient initially received twice-daily doses of slow-release TP 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity, on the basis of the clinical response. The following parameters were recorded at weekly intervals for 4 weeks: pain and opioid-related adverse effects, quality of life measured with the Spitzer score, TP escalation index percent (TPEI%) and TP escalation index in mg (TPE…

MaleSettore MED/41 - AnestesiologiaPainNeuropathic painCancer pain Neuropathic pain Opioids Tapentadol AnalgesiaQuality of lifePhenolsNeoplasmsMedicineCancer pain; Neuropathic pain; Opioids; Tapentadol; Aged; Analgesics; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Phenols; Prospective Studies; Medicine (all)HumansProspective StudiesCancer painAdverse effectProspective cohort studyAgedPain MeasurementAnalgesicsbusiness.industryMedicine (all)General MedicineMiddle AgedTapentadolClinical trialOpioidsTapentadolTolerabilityAnesthesiaNeuropathic painFemaleCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct